CIK 0001841387 · <br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,244,783
- in 2 filings, $3.2M under 10b5-1 plans
Net −$3,244,783. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-03 | Ostrovsky Maria General Counsel | Grant or award · Stock Option (Right to Buy) | +315,000 | 315,000 | ||
| 2026-09-30 | Loggia Nicoletta Director | Grant or award · Stock Option (Right to Buy) | +380 | $8.68 | $3K | 380 |
| 2026-09-30 | PAPA JOSEPH C Director | Grant or award · Stock Option (Right to Buy) | +1,325 | $8.68 | $11K | 1,325 |
| 2026-09-30 | Manning Paul B Director | Grant or award · Stock Option (Right to Buy) | +2,189 | $8.68 | $19K | 2,189 |
| 2026-09-11 | Tak Paul Peter Chief Executive Officer | Sale 10b5-1 | −59,379 | $10.46 | $621K | 113,321 |
| 2026-09-10 | Tak Paul Peter Chief Executive Officer | Option exercise 10b5-1 | +125,000 | $1.55 | $194K | 393,566 |
| 2026-09-10 | Tak Paul Peter Chief Executive Officer | Sale 10b5-1 | −220,866 | $11.50 | $2.5M | 172,700 |
| 2026-09-10 | Tak Paul Peter Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −125,000 | 1,638,968 | ||
| 2026-09-08 | Zimmermann Martine Director | Grant or award · Stock Option (Right to Buy) | +64,000 | 64,000 | ||
| 2026-08-17 | Tyagarajan Seshu Chief Technology Officer | Sale 10b5-1 | −7,000 | $12.00 | $84K | 76,865 |
| 2026-07-06 | Sims Mark E. Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +285,000 | 285,000 | ||
| 2026-06-30 | Loggia Nicoletta Director | Grant or award · Stock Option (Right to Buy) | +381 | $8.64 | $3K | 381 |
| 2026-06-30 | Manning Paul B Director | Grant or award · Stock Option (Right to Buy) | +2,199 | $8.64 | $19K | 2,199 |
| 2026-06-30 | PAPA JOSEPH C Director | Grant or award · Stock Option (Right to Buy) | +1,331 | $8.64 | $11K | 1,331 |
| 2026-06-29 | Tyagarajan Seshu Chief Technology Officer | Sale 10b5-1 | −7,000 | $10.02 | $70K | 83,865 |
| 2026-06-29 | Barone Francesca Chief Scientific Officer | Sale 10b5-1 | −23,447 | $10.06 | $236K | 77,362 |
| 2026-06-23 | Radhakrishnan Maha Director | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2026-06-23 | Loggia Nicoletta Director | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2026-06-23 | Martell Christopher Director | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2026-06-23 | Nabel Gary J. Director | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 |
Page 1 of 13 · 249 trades